Abstract
Autism spectrum disorders (ASD) are a cluster of developmental disorders, whose core symptoms can be attributed to abnormal development of the large-scale neural networks required for social communication. The impaired delivery of afferent signals has been proposed to be associated with impaired social interaction in ASD. Arachidonic acid (ARA) and docosahexaenoic acid (DHA) play key roles in the maturation of brain network. In particular, ARA promotes signal transduction related to neural function. It is therefore possible that supplementation with larger ARA doses added to DHA may mitigate the impaired social interaction observed in ASD. There have been no double-blind randomized placebo-controlled studies of the effect of large doses of ARA, added to DHA, on the impaired social interactions observed in ASD. This article presents the results of a 16-week double-blind randomized placebo-controlled trial in which high-dose ARA was added to DHA supplementation in individuals with ASD (n=13). The primary outcomes were measured using the Social Responsiveness Scale (SRS) and the secondary outcome measure was Autism Diagnostic Interview-revised (ADI-R) social and communication domains. Supplementation of larger doses of ARA added to DHA significantly improved SRS-measured communication and ADI-measured social communication. At the end of trial, the increase in plasma ARA levels from the baseline observed in the ARA treatment group was significantly higher compared to placebo group.
Keywords: Autism spectrum disorders, impaired social interaction, arachidonic acid, dietary supplementation, clinical trial, signal transduction
Current Psychopharmacology
Title:Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Volume: 2
Author(s): K. Yui, K. Koshiba and S. Nakamura
Affiliation:
Keywords: Autism spectrum disorders, impaired social interaction, arachidonic acid, dietary supplementation, clinical trial, signal transduction
Abstract: Autism spectrum disorders (ASD) are a cluster of developmental disorders, whose core symptoms can be attributed to abnormal development of the large-scale neural networks required for social communication. The impaired delivery of afferent signals has been proposed to be associated with impaired social interaction in ASD. Arachidonic acid (ARA) and docosahexaenoic acid (DHA) play key roles in the maturation of brain network. In particular, ARA promotes signal transduction related to neural function. It is therefore possible that supplementation with larger ARA doses added to DHA may mitigate the impaired social interaction observed in ASD. There have been no double-blind randomized placebo-controlled studies of the effect of large doses of ARA, added to DHA, on the impaired social interactions observed in ASD. This article presents the results of a 16-week double-blind randomized placebo-controlled trial in which high-dose ARA was added to DHA supplementation in individuals with ASD (n=13). The primary outcomes were measured using the Social Responsiveness Scale (SRS) and the secondary outcome measure was Autism Diagnostic Interview-revised (ADI-R) social and communication domains. Supplementation of larger doses of ARA added to DHA significantly improved SRS-measured communication and ADI-measured social communication. At the end of trial, the increase in plasma ARA levels from the baseline observed in the ARA treatment group was significantly higher compared to placebo group.
Export Options
About this article
Cite this article as:
Yui K., Koshiba K. and Nakamura S., Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010084
DOI https://dx.doi.org/10.2174/2211556011302010084 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Current Neuropharmacology Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Monoamine Oxidase B Inhibitors in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The α2δ Subunit and Absence Epilepsy: Beyond Calcium Channels?
Current Neuropharmacology 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Medicinal Chemistry Liquid Chromatography-Mass Spectrometry Method for the Determination of Olanzapine in Human Plasma and Application to a Bioequivalence Study
Current Pharmaceutical Analysis Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century – A Medicinal Chemistry Survey
Current Topics in Medicinal Chemistry Significance of MRI Guided Focused Ultrasound Thalamotomy for Parkinson’s Disease: A Review
Current Medical Imaging Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives
CNS & Neurological Disorders - Drug Targets Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
CNS & Neurological Disorders - Drug Targets Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Therapeutic Strategies in Parkinsons Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
Current Neuropharmacology Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Current Neuropharmacology Pulmonary Defence Mechanisms
Current Respiratory Medicine Reviews